BioSpace News Archive

Eisai to Present Latest Data on Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination and Exploratory Research

On a Structurally Novel Class of Sting Agonist at 33rd Sitc Annual Meeting

November 6, 2018
·
4 min read
Business

Lonza Continues Strong Momentum in Businesses Along the Healthcare Continuum in Q3 2018 and Confirms Positive Outlook for the Full Year

Businesses in Pharma & Biotech and in Consumer Health – including capsule and combined ingredient and dosage form offerings – continued to drive growth

November 6, 2018
·
8 min read
Business

Pharming Group reports interim financial results for the first nine months of 2018

Pharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.

November 6, 2018
·
15 min read
Scientists uncover why knee joint injury leads to osteoarthritis

Knee joint injuries are typically related to sports, such as football, rugby or ice hockey, but people often do not know that such injuries may lead to joint inflammation and post-traumatic osteoarthritis.

November 6, 2018
·
2 min read
Drug Development

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, A Novel Gene Therapy for Patients with Parkinson’s Disease

Initial data from the first cohort expected in first half of 2019

November 6, 2018
·
6 min read
Drug Development

Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer

Cristal Therapeutic announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer.

November 6, 2018
·
2 min read
Policy

Manufacturing licence restriction at Recipharm Ltd, Ashton-u-Lyne, UK facility

Following a routine audit, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) have restricted the manufacturing licence for five non-critical highly potent products supplied from the Recipharm facility located in Ashton-u-Lyne, UK.

November 6, 2018
·
2 min read
Business

Achaogen Initiates Strategic Review, Plans Significant Cut to Operating Expenses

Shares of South San Francisco-based Achaogen, Inc. fell more than 12 percent in Monday trading after the company signaled that it began a review of strategic alternatives that could include a sale of the company.

November 6, 2018
·
2 min read
·
Alex Keown
Business

Allergan Backs off From $200 Million Plant Expansion in Waco, Texas

Allergan indicated that it “has shifted [its] priority from expanding the Waco site to investing significantly in our existing operations.” However, the company spokesperson said that Allergan “remains committed to our eye care business and operations in Waco.”

November 6, 2018
·
2 min read
·
Mark Terry
Business

Eli Lilly Pushes Full Steam Ahead on Immuno-Oncology With NextCure Pact

Lilly is paying NextCure $25 million upfront. NextCure will be eligible for various development and commercial milestone payments, as well as royalties on any commercial products. In addition, Lilly invested $15 million in NextCure equity.

November 6, 2018
·
3 min read
·
Mark Terry